Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+
Multiple myeloma (MM) derives from malignant transformation of plasma cells (PC), which accumulate in the bone marrow (BM), where microenvironment supports tumor growth and inhibits anti-tumor immune responses. Adenosine (ADO), an immunosuppressive molecule, is produced within MM patients' BM b...
Main Authors: | F. Morandi, D. Marimpietri, A. L. Horenstein, M. Bolzoni, D. Toscani, F. Costa, B. Castella, A. C. Faini, M. Massaia, V. Pistoia, N. Giuliani, F. Malavasi |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-08-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2018.1458809 |
Similar Items
-
NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model
by: Alberto L. Horenstein, et al.
Published: (2015-09-01) -
Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells
by: Fabio Morandi, et al.
Published: (2019-05-01) -
The Thyrotropin-Releasing Hormone-Degrading Ectoenzyme, a Therapeutic Target?
by: Jean-Louis Charli, et al.
Published: (2020-05-01) -
Realization of Osteolysis, Angiogenesis, Immunosuppression, and Drug Resistance by Extracellular Vesicles: Roles of RNAs and Proteins in Their Cargoes and of Ectonucleotidases of the Immunosuppressive Adenosinergic Noncanonical Pathway in the Bone Marrow Niche of Multiple Myeloma
by: Takashi Watanabe
Published: (2021-06-01) -
Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule
by: Antonella Chillemi, et al.
Published: (2013-04-01)